Axonics® Announces Publication of Fecal Incontinence Study Results for Patients Treated with r-SNM® System

IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, today announced the publication of fecal incontinence study results for patients treated with the Axonics r-SNM System. The study results were published in the peer-reviewed journal Neuromodulation, the official journal of the Interna

Click to view original post